The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysisResearch in context
Summary: Background: In hormone-receptor positive/HER2-negative metastatic breast cancer (mBC) no randomized comparisons are available between CDK4/6 inhibitors. We undertook this systematic review and meta-analysis to assess the reliability of the likelihood of being helped or harmed (LHH). Method...
Main Authors: | Luca Mastrantoni, Armando Orlandi, Antonella Palazzo, Giovanna Garufi, Alessandra Fabi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-02-01
|
Series: | EClinicalMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537023000019 |
Similar Items
-
Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom
by: Luigino Calzetta, et al.
Published: (2021-04-01) -
Significance of Clinical and Laboratory Variables in Early Detection and Prognosis of Malignant Lymphoma
by: Aiyesha Humaira
Published: (2017-12-01) -
The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
by: Giovanna Garufi, et al.
Published: (2021-10-01) -
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
by: Jesús Fuentes-Antrás, et al.
Published: (2020-12-01) -
Evidence-Based Medicine (EBM) and Decision Tools (Out of Print)
by: Alan Schwartz
Published: (2006-06-01)